Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 28, 2023 16:05 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
August 09, 2023 16:03 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Initiation of Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF INTEGRIS-PSC Phase 2a 12-week data of bexotegrast in patients with PSC expected in the third quarter of 2023 ...
August 09, 2023 08:00 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
July 25, 2023 08:00 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
June 23, 2023 07:30 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

SOUTH SAN FRANCISCO, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
May 24, 2023 08:00 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
May 10, 2023 08:05 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics to Participate in Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
May 09, 2023 16:02 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Positive long-term data from INTEGRIS-IPF 320 mg dose group at 24-weeks demonstrated bexotegrast was well tolerated with durable improvement shown across multiple measures INTEGRIS-PSC...
April 30, 2023 14:10 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative to standard...
April 12, 2023 08:01 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...